Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk

Published:2017-06 Issue: Volume:104 Page:1-4
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Drake Marcus J.^ORCID,MacDiarmid Scott,Al-Shukri Salman,Barkin Jack,Fianu-Jonasson Aino,Herschorn Sender,Huang Moses,Stoelzel Matthias,Siddiqui Emad

Funder

Allergan

Astellas Pharma Europe

Astellas Pharma US

Astellas Pharma

Ipsen

Ferring Pharmaceuticals

Publisher

Elsevier BV

Subject

Urology

Reference24 articles.

1. Urinary retention and post-void residual urine in men: separating truth from tradition;Kaplan;J Urol,2008

2. Acute urinary retention;Choong;BJU Int,2000

3. Female chronic urinary retention;Deane;Br J Urol,1985

4. Incidence rates and risk factors for acute urinary retention: the health professionals followup study;Meigs;J Urol,1999

5. Natural history of prostatism: risk factors for acute urinary retention;Jacobsen;J Urol,1997

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment;Gazi Medical Journal;2024-04-01

2. Inhibition of prejunctional parasympathetic pathways by β3-adrenoceptor agonists in the isolated pig detrusor: comparison with human detrusor studies;Frontiers in Pharmacology;2023-05-10

3. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults;Cochrane Database of Systematic Reviews;2023-05-09

4. Efficacy and safety of tamsulosin vs its combination with mirabegron in the management of lower urinary tract non‐neurogenic overactive bladder symptoms (OABS) because of Benign Prostatic Enlargement (BPE)‐An open label randomised controlled clinical study;International Journal of Clinical Practice;2021-04-19

5. Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB);Current Urology Reports;2019-05-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3